Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07204080 | (TNX-1500) in Kidney Transplant Recipients | PHASE2 | NOT YET_RECRUITING | 5 | — | — | Jul 1, 2026 | Jun 30, 2029 | Feb 25, 2026 | 2 | United States |
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).
The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at 12-months (Day 364, Week 52).
| Arm | Type | Description |
|---|---|---|
| Kidney Transplant Recipient | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TNX-1500 | DRUG | This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients. |
| Kidney Transplant | PROCEDURE | Kidney Transplant |
Inclusion Criteria: 1. Male or female subjects ≥18 to 75 years of age. 2. Kidney transplant candidates with chronic kidney disease (stage IV or V) or end-stage kidney disease evaluated and listed for transplantation at Massachusetts General Hospital. 3. Recipient of an ABO-compatible, non-human leu...